Literature DB >> 18931704

[Inoculation of murine bone marrow mesenchymal stem cells induces tumor necrosis in mouse with orthotopic hepatocellular carcinoma].

Han fang Jiang1, Jun Ren.   

Abstract

OBJECTIVE: To observe whether murine bone marrow mesenchymal stem cells (MSCs) implantation improves the survival of hepatocellular carcinoma (HCC)-bearing mice,and to investigate whether MSCs can differentiate to hepatocytes in HCC microenvironment in a mouse model of orthotopic HCC and its effects on tumor cells.
METHODS: Murine bone morrow MSCs were obtained through adherent culture method combined with magnetic cell sorting CD45(-), CD11b(-)cells, labeled with CFSE in vitro. Phenotypes of MSCs were analyzed by flow cytometry. A murine model of orthotopic HCC was induced by intrahepatic injection of 5 x 10(5) murine H22 hepatoma cells in a BALB/c mouse. In this experiment,twelve BALB/c mice were randomly divided into MSCs implantation and saline administration groups on the 7th day after establishment of orthotropic HCC. CFSE labeled MSCs were injected into tumor and/or normal liver tissue in MSCs implantation group. The life span of HCC-bearing mice was observed. After three weeks, albumin was determined by immunohistochemistry. The livers of HCC-bearing mice were observed by light microscopy.
RESULTS: In MSCs group, the mean survival time was 25 days (95% Confidence interval: 22-28 d), while, in the control group, mean survival time was 21 days (95% CI: 20-23 d). However, the statistical difference was not obvious between the two groups (P = 0.0713). It showed that the CFSE labeled cells mainly localized in the border of tumor, also a few in the tumor bed, and expressed albumin. Interestingly, there was a larger area of necrosis in the tumor bed, compared with that in the controls.
CONCLUSION: It can be concluded that MSCs not only could engraft in livers of carcinoma-bearing BALB/c mice, but also could differentiate to hepatocyte-like cell. At the same time, MSCs might induce tumor cells necrosis. Further mechanism need to be studied.

Entities:  

Mesh:

Year:  2008        PMID: 18931704

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  4 in total

1.  Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells.

Authors:  Bo Ma; Hanfang Jiang; Jun Jia; Lijun Di; Guohong Song; Jing Yu; Yulin Zhu; Zhihao Lu; Xiaoli Wang; Xinna Zhou; Jun Ren
Journal:  Clin Transl Oncol       Date:  2012-07-27       Impact factor: 3.405

2.  Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study.

Authors:  Tianran Li; Bin Song; Xiangke Du; Zhengmao Wei; Tianlong Huo
Journal:  Eur J Med Res       Date:  2013-09-30       Impact factor: 2.175

3.  Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC.

Authors:  Saieh Hajighasemlou; Mohsen Nikbakht; Saeedreza Pakzad; Samad Muhammadnejad; Safoora Gharibzadeh; Milad Mirmoghtadaei; Fariba Zafari; Iman Seyhoun; Jafar Ai; Javad Verdi
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-14       Impact factor: 2.629

4.  Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.

Authors:  Erika L Spaeth; Jennifer L Dembinski; A Kate Sasser; Keri Watson; Ann Klopp; Brett Hall; Michael Andreeff; Frank Marini
Journal:  PLoS One       Date:  2009-04-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.